A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

NCT00962832 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

238

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Placebo
DRUG: Rontalizumab

Sponsor

Genentech, Inc.